BioCentury | Jan 4, 2019
Clinical News

Almirall's nail solution of terbinafine meets in Phase III for onychomycosis

Almirall S.A. (Madrid:ALM) said P-3058 met the primary endpoint vs. vehicle of improving complete cure rate in a Phase III trial to treat mild-to-moderate onychomycosis. Complete cure was defined as a composite of negative potassium...
BioCentury | Jul 20, 2018
Clinical News

Scynexis planning Phase III program for vulvovaginal candidiasis candidate

Scynexis Inc. (NASDAQ:SCYX) said all five dose regimens of oral SCY-078 showed "meaningful clinical and mycological activity" in the double-blind, U.S. Phase IIb DOVE trial in 186 patients with moderate to severe acute vulvovaginal candidiasis....
BioCentury | Apr 20, 2018
Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

Cidara Therapeutics Inc. (NASDAQ:CDTX) reported top-line data from 92 patients with candidemia and/or invasive candidiasis in the modified intent-to-treat (ITT) population of the Phase II STRIVE trial showing that once-weekly 400 mg IV rezafungin (formerly...
BioCentury | Jul 13, 2017
Clinical News

Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported top-line data from a Phase II trial to treat moderate to severe vulvovaginal candidiasis showing that oral CAmB (MAT2203) met the primary safety endpoint but missed the secondary efficacy...
BioCentury | Apr 14, 2017
Clinical News

SB208: Ph II NI-AF201 data

Top-line data from 126 patients with tinea pedis in the modified intent-to-treat (mITT) population of a double-blind, Dominican Phase II NI-AF201 trial showed that once-daily 4% and 16% topical SB208 each met the primary endpoint...
BioCentury | Apr 12, 2017
Clinical News

Novan gains on Phase II athlete's foot readout

Novan Inc. (NASDAQ:NOVN) rose $1.90 (21%) to $6.29 on Wednesday after it said the two highest doses of SB208 met the primary endpoint in a Phase II trial to treat tinea pedis, or athlete's foot....
BioCentury | Feb 24, 2017
Clinical News

CD101 Topical: Phase II RADIANT data

Top-line data from 89 patients with moderate to severe acute vulvovaginal candidiasis in the modified intent-to-treat (ITT) population of the open-label, U.S. Phase II RADIANT trial showed that CD101 topical gel and ointment led to...
BioCentury | Feb 21, 2017
Clinical News

Cidara discontinues CD101 topical for vulvovaginal candidiasis

Cidara Therapeutics Inc. (NASDAQ:CDTX) plummeted $4.50 (38%) to $7.20 on Tuesday after discontinuing development of CD101 topical to treat vulvovaginal candidiasis. Both gel and ointment formulations of the product led to lower clinical and mycological...
BioCentury | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb RENOVATE data

Additional data from the double-blind, U.S. Phase IIb RENOVATE trial in 259 patients with distal lateral subungual onychomycosis of the large toenail showed that 300 and 600 mg doses of oral VT-1161 once daily for...
BioCentury | Oct 24, 2016
Clinical News

SCY-078: Additional Phase II data

Additional data from 14 patients with invasive candidiasis who were initially treated with IV echinocandin in an open-label, international Phase II trial showed that there were no reports of mycological failure in patients receiving 750...
Items per page:
1 - 10 of 105
BioCentury | Jan 4, 2019
Clinical News

Almirall's nail solution of terbinafine meets in Phase III for onychomycosis

Almirall S.A. (Madrid:ALM) said P-3058 met the primary endpoint vs. vehicle of improving complete cure rate in a Phase III trial to treat mild-to-moderate onychomycosis. Complete cure was defined as a composite of negative potassium...
BioCentury | Jul 20, 2018
Clinical News

Scynexis planning Phase III program for vulvovaginal candidiasis candidate

Scynexis Inc. (NASDAQ:SCYX) said all five dose regimens of oral SCY-078 showed "meaningful clinical and mycological activity" in the double-blind, U.S. Phase IIb DOVE trial in 186 patients with moderate to severe acute vulvovaginal candidiasis....
BioCentury | Apr 20, 2018
Clinical News

Cidara reports Phase II data for IV antifungal rezafungin

Cidara Therapeutics Inc. (NASDAQ:CDTX) reported top-line data from 92 patients with candidemia and/or invasive candidiasis in the modified intent-to-treat (ITT) population of the Phase II STRIVE trial showing that once-weekly 400 mg IV rezafungin (formerly...
BioCentury | Jul 13, 2017
Clinical News

Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis

Matinas BioPharma Holdings Inc. (NYSE-M:MTNB) reported top-line data from a Phase II trial to treat moderate to severe vulvovaginal candidiasis showing that oral CAmB (MAT2203) met the primary safety endpoint but missed the secondary efficacy...
BioCentury | Apr 14, 2017
Clinical News

SB208: Ph II NI-AF201 data

Top-line data from 126 patients with tinea pedis in the modified intent-to-treat (mITT) population of a double-blind, Dominican Phase II NI-AF201 trial showed that once-daily 4% and 16% topical SB208 each met the primary endpoint...
BioCentury | Apr 12, 2017
Clinical News

Novan gains on Phase II athlete's foot readout

Novan Inc. (NASDAQ:NOVN) rose $1.90 (21%) to $6.29 on Wednesday after it said the two highest doses of SB208 met the primary endpoint in a Phase II trial to treat tinea pedis, or athlete's foot....
BioCentury | Feb 24, 2017
Clinical News

CD101 Topical: Phase II RADIANT data

Top-line data from 89 patients with moderate to severe acute vulvovaginal candidiasis in the modified intent-to-treat (ITT) population of the open-label, U.S. Phase II RADIANT trial showed that CD101 topical gel and ointment led to...
BioCentury | Feb 21, 2017
Clinical News

Cidara discontinues CD101 topical for vulvovaginal candidiasis

Cidara Therapeutics Inc. (NASDAQ:CDTX) plummeted $4.50 (38%) to $7.20 on Tuesday after discontinuing development of CD101 topical to treat vulvovaginal candidiasis. Both gel and ointment formulations of the product led to lower clinical and mycological...
BioCentury | Jan 13, 2017
Clinical News

VT-1161: Additional Ph IIb RENOVATE data

Additional data from the double-blind, U.S. Phase IIb RENOVATE trial in 259 patients with distal lateral subungual onychomycosis of the large toenail showed that 300 and 600 mg doses of oral VT-1161 once daily for...
BioCentury | Oct 24, 2016
Clinical News

SCY-078: Additional Phase II data

Additional data from 14 patients with invasive candidiasis who were initially treated with IV echinocandin in an open-label, international Phase II trial showed that there were no reports of mycological failure in patients receiving 750...
Items per page:
1 - 10 of 105